Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Alkali or alkaline earth chloride
Reexamination Certificate
2002-11-12
2004-12-28
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Alkali or alkaline earth chloride
C424S457000, C424S468000, C424S601000, C424S682000, C424S683000, C424S686000, C424S688000, C424S689000, C424S692000, C424S697000, C424S722000, C514S557000, C514S558000, C514S560000, C514S561000, C514S568000, C514S574000, C514S867000, C514S905000, C514S964000
Reexamination Certificate
active
06835398
ABSTRACT:
FIELD OF THE INVENTION
This invention is in the field of oral pharmaceuticals, and especially in pain management.
BACKGROUND
Magnesium is the seventh most plentiful element in the human body and the most common intracellular divalent cation. A cofactor in hundreds of enzymatic processes, including all enzymes utilizing adenosine triphosphate, magnesium's multiple physiologic effects have been recognized for decades. Clinical studies have suggested that magnesium, as a pharmacologic agent, may be beneficial in many disorders including asthma, cardiac arrhythmias, eclampsia, headaches including migraines, hypertension, mania, mitral valve prolapse, muscle cramps, pain syndromes, various menstrual symptoms, seizures, tetanus, and vasospastic disorders. However, the results from various studies have not been unequivocal. These varied results may be due in part to the limited pharmacologic effects of usual oral dosages of 250-500 mg/day, doses that hardly differ from the recommended daily allowances for magnesium of 350 mg/day for women and 420 mg/day for men. The use of higher oral doses has typically been precluded because of magnesium's tendency to provoke diarrhea in many patients when administered orally. For example, in one study a dosage of 250 mg two times daily of magnesium administered orally produced adverse effects in 45.7% of subjects. Yet oral dosing is without question the administration route of choice. Intravenous drug administration requires that the patient be in a hospital or clinic. Where the condition being treated is chronic, this is impractical. Oral administration at pharmacologic doses is key to treating chronic conditions. However oral dosing at pharmacologic levels has heretofore been ineffective due to the inability of patients to tolerate such a regimen.
The inventors have developed a method for successfully introducing high doses of oral magnesium without the tolerance problems previously associated with high oral dosing. This high oral dose magnesium is particularly useful in the treatment of intractable erythromelalgia (EM), neuropathic conditions, and other related neurovascular disorders, and has produced startling results in the management of pain and other symptoms associated with these diseases.
SUMMARY OF THE INVENTION
A method of treating patients, particularly for pain associated with diseases including erythromelalgia, chronic regional pain syndrome, and reflex sympathetic dystrophy, involves orally administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium (600 mg to 5 gm elemental magnesium). These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and using a more well-tolerated form of magnesium preferably a magnesium solution. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.
A method for treating a patient with magnesium supplementation comprising:
introducing said patient to a treatment regimen wherein orally administered magnesium dosage levels increase gradually over time from about 250 to 500 mg elemental magnesium/day to between about 600 mg and about 5000 mg/day elemental magnesium, wherein (i) each orally administered daily dosage amount is (a) in extended release form and/or (b) divided into smaller doses and orally administered several times per day, (ii) the orally administered daily dosage amount is gradually increased over time and in association with patient's increased tolerance to the increased dosage, and (iii) the administered magnesium is in a solid form or a solution; and
maintaining a well-tolerated high-level dosage of orally administered magnesium until therapeutically effective magnesium supplementation is obtained.
REFERENCES:
patent: RE34222 (1993-04-01), Bloch
patent: 5654011 (1997-08-01), Jackson et al.
patent: 5914129 (1999-06-01), Mauskop
patent: 6159505 (2000-12-01), Piper
patent: 6218192 (2001-04-01), Altura et al.
patent: 6500450 (2002-12-01), Hendrix
Kvernebo, K. “Erythromelalgia: A Condition Caused by Microvascular Arteriovenous Shunting.”VASA, Nov. 1998; Supplement 51:1-40.
Drug Facts and Comparisons, Facts and Comparisons, Chapter 1, Nutritional Products, a Wolters Kluwer Company, St. Louis, 1993-1997.
Mangat, H.S., “Nebulized Magnesium Sulphate Versus Nebulized Salbutamol in Acute Bronchial Asthma: A Clinical Trial”,European Respiratory Journal, Aug. 1998, 12(2):341-4.
Sueta, C.A. et al, “Antiarrhythmic Action of Pharmacological Administration of Magnesium in Heart Failure: A Critical Review of New Data”,Magnesium Research, Dec. 1995, 8(4):389-401.
Saris NE; Mervaala E; Karppanen H; Khawaja JA; Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects.Clinica Chimica Acta,Apr. 2000, 294(1-2):1-26.
Mauskop, A. et al., “Intravenous Magnesium Sulfate Rapidly Alleviates Headaches of Various Types”,Headache, Mar. 1996, 36(3):154-60.
Mauskop, A., “Role of Magnesium in the Pathogenesis and Treatment of Migraines”,Clinical Neuroscience, 1998, 5(1):24-7.
Itoh, K. et al., “The Effects of High Oral Magnesium Supplementation on Blood Pressure, Serum Lipids and Related Variables in Apparently Healthy Japanese Subjects”British Journal of Nutrition, Nov. 1997, 78(5):737-50.
Ryan, M.P., et al., “The Role of Magnesium in the Prevention and Control of Hypertension”,Annals of Clinical Research, 1984, 16 Suppl 43:81-8.
Widman, L., et al., “The Dose-Dependent Reduction in Blood Pressure Through Administration of Magnesium, A Double Blind Placebo Controlled Cross-Over Study”,American Journal of Hypertension,Jan. 1993, 6(1):41-5.
Gianni, A.J. et al., “Magnesium Oxide Augmentation of Verapamil Maintenance Therapy in mania”,Psychiatry Research, Feb. 14, 2000, 93(1):83-7.
Galland, L.D., et al., “Magnesium Deficiency in the Pathogenesis of Mitral Valve Prolapse”,Magnesium, 1986, 5(3-4):165-74.
Bilbey, D.L., “Muscle Cramps and Magnesium Deficiency: Case Reports”,Canadian Family Physician, Jul. 1996, 42:1348-51.
Crosby, V., et al., “The Safety and Efficacy of a Single Dose (500 mg or 1g) of Intravenous Magnesium Sulfate in Neuropathic Pain Poorly Responsive to Stong Opioid Anagesics in Patients with Cancer”,Journal of Pain and Symptom Management, Jan. 2000, 19(1):35-9.
Tanaka, M., et al. “Relief of Neuropathic Pain with Intravenous Magnesium”Masui. Japanese Journal of Anesthesiology, Sep. 1998, 47(9):1109-13. Abstract.
Koinig, H., “Magnesium Sulfate Reduces Intra-and Postoperative Analgesic Requirements”,Anesthesia and Analgesia, Jul. 1998 87(1):206-10.
Facchinetti, F., et al., “Oral Magnesium Successfully Relieves Premenstrual Mood Changes”,Obstetrics and Gynecology, Aug. 1991 78(2):177-81.
De Souza, M.C., et al., “A Synergistic Effect of a Daily Supplement for 1 Month of 200mg Magnesium Plus 50mg Vitamin B6 for the Relief of Anxiety-Related Premenstrual Symptoms: A Randomized, Double-Blind, Crossover Study,”Journal of Women's Health&Gender-Based Medicine, Mar. 2000, 9(2):131-9.
James, M.F., et al., “The Use of Magnesium Sulphate Infusions in the Management of Very Severe Tetanus”,Intensive Care Medicine, 1985, 11(1):5-12.
Ringvist, I., et al., “Effects of Cold Pressor Test on Circulating Atrial Natriuretic Peptide 99-126 (ANP) in patients with Raynaud's Phenomenon and Influence of Treatment with Magnesium Sulphate and Nifedipine”,Clinical Physiology, May 1993, 13(3):271-80.
Myrdal, U., et al., “Magnesium Sulphate Infusion Decreases Circulating Calcitonin Gene-Related Peptide (CGRP) in Women with Primary Raynaud's Phenomenon”,Clinical Physiology, Sep. 1994, 14(5):539-46.
Pfaffenrath, V., et al., “Magnesium in the Prophylaxis of Migraine-A Double Blind Placebo Controlled Study”,Cephalagia, Oct. 1996, 16(6):436-40.
Belch, J.L. “Temperature-Associated Vascular Disorders: Raynaud's Phenomenon and Erythromelalgia”, Chapter 22 in Lowe, GD, Tooke, JE,A Textbook of Vascular Medicine, London: Oxford University Press, 1996.
Lepper, J., et al., “Effect of Magnesiu
Pak John
Piper Rudnick LLP
LandOfFree
Method of administering high-dose, oral magnesium for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of administering high-dose, oral magnesium for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of administering high-dose, oral magnesium for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3273610